Published in Nat Rev Endocrinol on October 27, 2017
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med (2017) 4.18
Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care (2015) 2.79
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care (2015) 2.27
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res (2015) 0.86
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med (2017) 0.82
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. Cell Metab (2017) 0.81
Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,367 Individuals in the Diabetes Prospective Follow-up and T1D Exchange Registries. Diabetes Care (2017) 0.81
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol (2017) 0.81